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Abstract. The tumour-Clostridium phenomenon describes the
specific affinity of spore forming anaerobes to tumour growth.
The discovery of strictly intratumoral tetanus toxicoinfections
in tumour-bearing mice after intravenous spore administration
gave the impulse to search for non-toxic clostridial isolates with
tumour-selective properties for clostridial biotherapy, i.e.
oncolysis, as well as serologic tumour diagnostics without
any toxic side-effects. Systematic studies of the oncolytic
process and its variables on diverse experimental tumours
and laboratory animals revealed that tumour liquefaction,
converting necrotic tumour parts to putrid abscesses filled
with masses of clostridial forms, stops sharply at the viable
rim of the blood-supplied tumour tissue. Similar results were
observed in clinical trials, particular of gliomas. Before
oncolysis is initiated, the first stage of clostridial multi-
plication in the vascularized tissue is inducing a humoural
immune response, preceded by phagocytic activity. The
majority of tumour-bearing laboratory and domestic animals,
so far tested serologically, clinical cancer patients as well,
responded with anti-rod antibodies and, independently, anti-
spore antibodies. Oncolytic and non-oncolytic Clostridia were
equally immunogenic. During the early, immunizing period of
clostridial proliferation, analytical tumour-tetanus experiments
were focused on potential relations between tumour growth
kinetics and rod proliferation. Based on realistic growth models
and target principles, computer simulations could reproduce
the results, i.e. cumulative curves of tetanus lethality in groups
of mice. Thus, crucial assumptions of the mathematical model
were ex post confirmed by further experiments. Our working
hypothesis concentrates on temporally hypoxic micro-niches
close to a pre-mitotic cell with enhanced oxygen demand which
can be utilized by anaerobes (randomly) located there. As early
immune reactions to clostridial antigens via phagocytosis and
humoural immune response will do without invasion in
necrobiotic avascular tumour areas, the pacemaker model of
tumour-Clostridium interplay extends the scope of genetically
engineered Clostridia to early treatment of metastases. Thus,
novel concepts, such as ‘Clostridia-directed enzyme prodrug-
therapy’ and ‘Combined bacteriolytic therapy’, together with
immune activation, can come into play.
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Over five decades, bacteriological research on tumour-
associated anaerobic spore forming bacteria has accumulated
a considerable amount of information and a variety of new
concepts in experimental and clinical oncology. Of great
importance was the systematic elucidation which convincingly
demonstrated that the growth of anaerobes can be strictly
interconnected with tumour growth. This fact revealed certain
characteristics of tumour biology which, in the long run, laid
the basis for a novel strategy aiming at a selective tumour
biotherapy including tumour diagnostics.
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The discovery of the tumour-tetanus phenomenon by Möse
(1) and, independently, the ‘experimentum crucis’ of Malmgren
and Flanigan (2) initiated an investigative pattern where the
systemic administration of anaerobes resulted in the exclusive
and cumulative bacterial multiplication in the tumour site. No
previous studies of bacterial effects on neoplasms reported
results of the exclusive localization inside the tumorous
tissues following the intentional systemic injection of the
microbes (3). According to Malmgren and Flanigan, tumour
growth with the inherent tendency of cell proliferation, its
alteration in the vascular system (4), the dominating anaerobic
glycolysis as established by Warburg (5), and the districts of
low oxygen tension in necrotic tumour centres (6) appears to
fulfill the expected growth requirements for certain species of
the genus Clostridium. This concept is in accordance with the
basic postulate of the generally accepted necrosis theory of
anaerobic infections.
In the Malmgren-Flanigan experiment, mice bearing
spontaneous mammary carcinomas, transplanted mammary
carcinomas, hepatomas, and fibrosarcomas as well as tumour-
free mice as controls were tested with intravenous injections
of detoxified spores of Clostridium tetani. All tumour-bearing
mice died of tetanus ~48 h after spore injection preceded by
the specific tetanus symptoms. It indicated the germination
of the tetanus spores, the replication of the vegetative forms,
that is the spore-free tetanus rods, finally the synthesis and
secretion of the lethal tetanotoxin. The toxin is distributed in
the organism and binding to the spinal cord. Large numbers
of vegetative forms of Clostridium tetani were exclusively
localized in tumorous areas, predominantly in the necrotic
central part of the tumour. All control animals survived without
any signs of tetanus. In healthy organs the anaerobic bacteria
did not find hypoxic niches which allow their proliferation.
2. Experimental approach to clostridial oncolysis
Animal studies. Proceeding from his observation in 1954, Möse
recognized the importance of the tumour-tetanus phenomenon
for its potential in tumour diagnostics. He started a screening
programme intended to identify non-toxic and non-pathogenic
clostridial strains to be tested for selective growth in the solid-
growing Ehrlich carcinoma of mice and in subsequent studies
for pyrogen-free spores in rabbits. Designated with strain
No. 55, Möse and Möse identified Clostridium butyricum,
renamed Clostridium oncolyticum, which they isolated from
soil (7). It belongs to Clostridium sporogenes ATCC 13732
with an extraordinary oncolytic capability and was found to
be the reference strain for further studies. They eventually
led to the concept of cancer biotherapy with spore forming
anaerobic bacteria. Further investigation revealed anaerobic
growth in tumours of various animal species as the basic
prerequisite for oncolysis. In contrast to anaerobes, the aerobic
spore forming bacteria, genus Bacillus, did not show any
oncolysis under comparable experimental conditions (8). In
this context, Warburg had realized the Malmgren-Flanigan
experiment and clostridial oncolysis as the confirmation of his
theory on facultative anaerobic glycometabolism of tumour
cells (9). The incongruous state of tumorous growth, that is the
three-dimensional proliferation pattern of tumour cells that is
not in harmony with the two-dimensional propagation of
endothelial cells, leads to the ineffective vascular supply with
progressively greater distances of quiescent and necrotizing
tumour cells in the increasingly avascular hypoxic tumour
areas (10).
In a series of experiments the oncolytic properties of a
variety of Clostridia species were tested versus a variety of
transplantable tumours in mice, rats, rabbits, and hamsters. A
conceptual framework of guiding rules was setup for further
practice-related and fundamental studies (11-15). According
to the investigators, the beginning of the logarithmic phase of
tumour growth in the ascitic form of the Ehrlich carcinoma and
of the solid-growing tumour with at least 2 g of tumour weight
proved to be optimal for the administration of Clostridium
oncolyticum spores because the partially spontaneous necrosis
obviously provides favourable conditions for larger portions
of spores to germinate and proliferate (12). Apart from a
critical tumour size and the mode of spore injection, spore
dose and time-dose relationship between the phases of
clostridial propagation would influence colliquative necrosis
and resporulation. Additional variables effect the oncolytic
potential and extent of the tumour liquefaction, such as the
germinative quality of the spores and, last but not least, the
host-determined immune reactions. In most cases the animals
did not survive extensive oncolysis. A curative outcome after
single spore administration was an exception. Generally, the
sensitivity of various transplantable tumours differed
considerably after oncolytic spore treatment, and in contrast
with the predominantly susceptible murine tumours, many rat
and rabbit tumours proved to be resistant.
To improve the effect of clostridial oncolysis and to
circumvent neoplastic resistance to oncolysis, experiments
were started which combined clostridial biotherapy with
conventional cytostatic treatment schedules, such as by suitable
adjustment of the antimetabolite 5-fluorodeoxyuridine which
significantly reduced the average tumour weight below that
resulting from the use of either agent alone (13). Noticeably,
Gericke and coworkers pointed the way to adjuvant physical
modes which turned out to be more successful through local
non-curative X-irradiation plus local microwave hyperthermia
preceding systemic spore administration. For the first time, a
distinct prolongation of life and 20% total tumour regression
were achieved on the transplanted Harding-Passey melanoma
of the mouse. Repeated applications of the triple combination
therapy were well tolerated with increased cure rates in cases
of relapsed tumours (16). Likewise, significant final cure rate
and prolongation of complete remission were observed with
the triple combination and repeated treatment for recurrence
of the oncolysis-resistant methylcholanthrene-induced fibro-
sarcoma of the mouse (17). 
Clinical trials. Before the beginning of preparatory studies
for examining patients with advanced neoplasms, safety and
side-effects of systemic Clostridium oncolyticum spores were
tested in a self-experiment by Möse, starting with a low
dose which was increased successively without any adverse
reactions. In the clinical approach, single doses of 1010 spores
applied intravenously were well tolerated followed by rising
temperature and leukocytosis within 4-8 days which were
accompanied by abundant clostridial propagation and pro-
gressive oncolysis. The process was comparable with reactions
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in animal tumours, to the extent that partial or total portions
of the tumour centre became liquefied converting the necrotic
tumour tissue into a putrid abscess, which contained masses of
vegetative clostridial rods, sporangia, and mature spores.
The oncolysis was interrupted sharply at the border of the
viable tumour tissue from which regrowth occurred. The bulk
of clostridial rods were to be found in necrotic layers on
the viable rim, and repeated spore injections were without
any harm (18-21). More information was collected about
malignant gliomas. The Clostridium oncolyticum spores were
administered by intracarotid injection and the oncolysis was
complete one week later. The glioblastoma had converted to
a brain abscess which had to be operated appropriately (22).
The rate of recurrence remained uninfluenced. Based upon
former clinical experience the clostridial oncolysis was
strongest in well vascularized gliomas. Daily computertomo-
graphic control set the time point for extirpation of the lysed
tumour residue. In low grade astrocytomas and poorly
vascularized gliomas the spores had little or no effect (23).
Altogether, the empirical data of these studies clearly pointed
the way towards a restrictive application of oncolytic spores
to defined clinical cases of cancer, allowing for balanced water
and electrolyte supply with alcalosis control as indispensible
means of supportive care (21).
Basic studies. A whole series of experimental studies have
been performed to elucidate the mechanisms which governed
the selective, temporarily unrestricted clostridial growth and
which formed the basis for the liquefaction of tumour tissue.
Diverse factors were taken into consideration. Basically, a low
partial pressure of oxygen with negative redox potential for
the anaerobic energy metabolism of Clostridium oncolyticum
(24); despite early vasculogenesis during the incipient invasive
phase of tumour cell aggregates (25), the progressive tumour
growth which is bearing upon abnormal and insufficient
vascular supply in the solid growing tumours gradually
outnumbers the process of endotheliogenesis (26,27).
Many experimental and human tumours contain poorly
vascularized and often necrotic central areas surrounded by a
well-vascularized rim of viable tumour cells. This will restrict
the oncolytic effects to the hypoxic tumour centres.
Special attention has been addressed to a number of extra-
cellular factors produced either by germinating spores or
vegetative forms of Clostridium oncolyticum. Fredette and
coworkers gave an account of a cytotoxic factor released from
germinating Clostridium oncolyticum spores which selectively
inhibited transplantable heteroploid cell lines in distinct
proportions of spores to eukaryotic cells, while diploid cell
lines remained unchanged (28,29). Similar effects were
observed by Schlechte et al (30).
Moreover, several extracellular hydrolases have been found
and characterized in supernatants of Clostridium oncolyticum
cultures. In particular, the investigation on clostridial kininases
(31) and their crucial pharmacophysiologic role in the tumour
kinin system leading to diminution and breakdown of the
microcirculation via bradykinin degradation (32) has clarified
the existence of proteases, peptidases (33), nucleases (34),
and phospholipase A (35). The growth curves of Clostridium
oncolyticum cultures and their exoenzyme activities showed
strict dependence on low redox potential (34).
Apart from clostridial hydrolases connected with oncolysis,
it could be proven by manometric technique that under 5%
CO2 N2 atmosphere metabolizing Ehrlich ascitic carcinoma
cells stimulated the germination and replication of Clostridium
butyricum 1672 A (McClung) spores in a modified Parker
medium. The clostridial growth showed concentric associations
with the tumour cell membrane (36): Fig. 1a and b. Even more
remarkable were Clostridium oncolyticum rods seen in contact
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Figure 1. Warburg-manometer experiment with Ehrlich ascitic carcinoma cells and Clostridium butyricum spores 1672 A (McClung): 10 ml modified Parker-
Medium with glucose, bicarbonate and 5x10-5 M Fe++, 5% CO2 in N2-atmosphere, 13-h incubation period. (a) 1x107 Clostridium butyricum spores 1672 A,
(b) 1.8x106 viable Ehrlich ascitic carcinoma cells and 1x107 Clostridium butyricum spores 1672 A.
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with the Ehrlich carcinoma cell membrane, not with normal
cells, which were replicating in obvious protection from the
mild aerobic milieu after cocultivation in monolayer cell
cultures under 1.5% O2 5% CO2 N2 atmosphere (30). In a
comparable manner and few hours after simultaneous, sub-
cutaneous injection of proliferative tumour cells with mature,
viable Clostridium butyricum 1672 A (McClung) spores, both
germinative and vegetative forms of Clostridium butyricum
could be detected histologically closely associated with
mitotic tumour cells of the Ehrlich carcinoma in a disc-like
accumulation of viable tumour cells (37). In this context, it is
important that Marth and Möse suggested a binding mech-
anism between Clostridium oncolyticum and tumour cell
through the clostridial neuraminidase reaction with N-acetyl-
neuraminic acid (NANA) among the glycolipid pattern of the
tumour cell membrane. In consequence, the early rise of
NANA in sera of tumour-bearing mice and humans marks an
incipient clostridial oncolysis (38,39).
In addition to the tumour-Clostridium interplay during
oncolysis between energy metabolism, substance metabolism,
and the kinin system, the application of clostridial spores with
subsequent multiplication of vegetative rods inside the tumour
activates the immune system. On the one hand, immunization
with M 55-rod vaccine totally abrogated the oncolytic effect of
Clostridium oncolyticum on solid growing Ehrlich carcinoma
of mice, while pretreatment of mice with prednisolone
significantly enhanced the oncolysis (40). On the other hand,
intravenously applied viable spores compared with a single
injection into the tumour of live, or heat-inactivated rods,
respectively, revealed oncolysis starting at the same time, i.e.
40 h after inoculation, but with a greater extent of lysis in
mice treated with live Clostridia. This pointed to differential
influence on oncolysis and the interdependence between
immunological and enzymatic mechanisms (41).
3. Examination of tumour diagnostic facilities
Experiments on laboratory animals. Due to the antigenic
tumour heterogenization (42), the concept of tumour detection
became realizable after the discovery of the selective
localization of vegetative clostridial forms in the Malmgren-
Flanigan experiment (2). Möse had this idea from the
beginning and turned to extending his experiments with
Clostridium oncolyticum into systematic studies by means of
serologic techniques (43). It soon became clear that, after
intravenous injection of Clostridium oncolyticum spores, a
significant rise of anti-rod antibodies in sera of tumour-bearing
mice and other animals is independent of the oncolytic process.
Moreover, it could be confirmed that the start of the humoural
immune response to the clostridial rod accumulation inside
the tumour does occur a few days after tumour transplantation
and spore application and clearly before the initiation, or even
in absence of oncolysis, respectively. Further essentials for
the introduction of clostridial rod antigens into a serologic
tumour test were the qualitatively different spore and rod
antigens, moreover, the quantitative equivalence of oncolytic
and non-oncolytic Clostridia with regard to the criteria of
intratumoral immunogenicity (44-46). In particular, the
precondition of detectability by the spore assay is the vasculari-
zation of the tumour tissue. Aerobic spore forming bacteria,
genus Bacillus, are unsuitable. Already in 1965 by using the
Widal agglutination and indirect hemagglutination tests,
Gericke had described serologic cross-reactions among
oncolytic clostridial strains on the one side, and non-oncolytic
strains on the other side (47,48). This was confirmed by
Sachse and Sachse (49).
When testing transplantable tumours of the rat, after
systemic Clostridium oncolyticum spore administration,
Kretschmer et al (50,51) observed distinct delays of antibody
response against rod antigens following cytostatic treatment
with regard to antibody titre dynamics of the untreated control
animals and early tumour growth. In another experiment, the
anti-rod antibody titre increase signalled ethylnitrosourea
induced brain tumours of the rat 2-4 weeks before clinical
signs of tumour growth became registered (52).
Schubert and Winkler (53) were the first to investigate the
localization of 8-10 days grown Yoshida sarcomas by I131-
labelled anti-rod antibodies in rats pretreated with Clostridium
oncolyticum spores. The validation of the results by tumour
scintigraphy was limited because non-specific intratumoral
concentration of nuclide-labelled antibodies in spore-free rats
could be demonstrated (54,55). In addition, scintigraphic
studies applying oncolytic Clostridia met with difficulties
concerning reproducibility of the experiments as the time
point of clostridial oncolysis which is most favourable for the
intratumoral accumulation of the nuclide-labelled anti-rod
antibodies varied and could not definitely be determined. At
the peak of clostridial oncolysis peripheral blood vessels
became obliterated blocking up the access to the liquefied
tumour centre with masses of diverse clostridial forms (39).
Further experiments with Cr51-labelled Clostridium butyricum
spores revealed preferential spore accumulation in the mono-
cyte-macrophage system, much less in the tumour site (56).
Experimental experience in veterinary medicine. According
to Möse (43), Möse and Möse (44), Möse and Gericke (45),
tumour-bearing laboratory animals formed antibodies to
clostridial rods which could be serologically distinguished
from anti-spore antibodies. Absence of anti-rod antibodies in
the period of observation following intravenous injection of
clostridial spores made the test negative. The test was
selectively tumour-reactive against intratumoral multiplying
clostridial rods and gave an indirect measure of tumour
growth by applying Clostridia serology. The test was more
sensitive than Clostridia induced tumour lysis. These findings
and the insight which was gained from the analytical tumour-
tetanus experiments, to be discussed later, initiated the
exploration of test facilities in veterinary medicine.
The investigation on spontaneous tumours of the dog
anticipated new options for comparative pathology and gave
the opportunity to gather experience for clinical studies in
human oncology. The dogs were patients of veterinary surgery
(57). The tumour was operated 10-14 days after intravenous
injection of 2x108 Clostridium butyricum spores per kg body
weight. Blood samples were taken before injection, 1-2 weeks,
and 2-3 weeks after tumour extirpation.
As the enzyme pattern of Clostridium oncolyticum
destroyed tumour tissue with contact sites to cell membranes,
with hemolytic effects, and attacked the tumour kinin system
at least a local pathologic action could not be denied (35).
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Therefore, careful selection and delineation of clostridial strains
for diagnostic purposes in domestic veterinary oncology
appeared obligatory. The choice of Clostridium butyricum
CNRZ 528 (58) turned out to be suitable and clearly differ-
entiated from Clostridium oncolyticum biologically using the
hamster-A Mel 3 assay (59) and biochemically as well as by
phage typing (60). Clostridium butyricum (beijerinckii) CNRZ
528 was saccharolytic, non-oncolytic, non-pathogenic, and had
been isolated from cheese (61). Its antigenic structure differed
qualitatively from Clostridium oncolyticum antigens (62).
After successive cloning of Clostridium butyricum CNRZ 528,
large batches of rod-free mature spores were prepared for
domestic animal trials by the Saxonian Serum Institute
Dresden, Branch II at Oelzschau. A total of 251 dogs, 153 with
malignant tumours, 59 with benign tumours, and of 39 tumour-
free control animals were included in this trial. Many malignant
tumours were mammary carcinomas (46%). The tumours had
been histopathologically evaluated independently from sero-
diagnosis and vice versa. The final judgement of the spore
assay was made by multivariate analysis of the comprehensive
serological reaction pattern with the histopathological findings
(62,63). The combined evaluation of the complement fixation
test and passive hemagglutination test resulted in 80% test
efficiency of the dogs with mesenchymal and mixed tumours
displaying more aggressive growth tendency as against 70%
of epithelial tumours.
Despite small numbers of horses, the serologic Clostridium-
tumour test rendered a rather satisfactory test result with 66%
positive cancer tests among 9 solid growing malignant tumours
and 5 negative tests of the 5 benign neoplasms (64). Injections
of 2x108 spores per kg body weight were made into the jugular
vein of the animals. A similar study on bovine leukosis virus
(BLV)-infected cattle was carried out which belonged to
different age groups and stages of infection (with and without
hematological alterations) and with incipient tumour develop-
ment (swelling of externally visible and palpable lymph
nodes). Of 6 BLV-infected and spore-treated (6-10 years old)
heads of cattle, 3 were spore-test positive and 3 (~4 months
old) cows were negative. The cows with positive test were
hematologically leukosis-positive with clinically enlarged
lymph nodes. By contrast, the 3 negative cows, hemato-
logically leukosis-positive, were without signs of tumorous
process. Moreover, 3 spore-treated BLV-free cows and 2 BLV-
infected animals with isotonic sodium chloride solution instead
of spore treatment were spore-test negative. Finally, 4 BLV-
infected and 2 BLV-free cattle, all of them without spore
injection, were spore-test negative. In consequence, the early
discrimination of tumorous from the non-tumorous BLV-
process lent support to a species-independent experience with
serologic Clostridium test-reactivity in veterinary oncology
(65). In this context, the examination of 5 green monkeys
with 10-fold systemic spore doses, compared to domestic
animals, gave further evidence for this argument: One animal
was cancer-test positive and had a mesothelioma measuring
~4 mm in diameter, vascularized, and invading the lung tissue.
The spore-test was done in a blind test (66).
Clinical studies. With their ‘Clostridial Oncolysis in Man’
study, Carey et al (21) had successfully introduced the
passive hemagglutination test for examining patients with
progressive carcinoma. In the same way, Möse and Möse
(67) were able to report increasing anti-rod agglutinin titres
of patients with mammary carcinoma following systemic
application of Clostridium oncolyticum spores.
As a live diagnostic agent the test spores were subject
to drug-testing regulations of the Drug-Act of the GDR (68)
as well as to guidelines for testing sera and vaccines (69).
Accordingly, tumour lysing clostridial strains were not feasible
for diagnostic purposes. In a comprehensive pharmaceutic-
immunological protocol, the safety of the test-spores had to be
proved on rodents, rabbits, dogs, and green monkeys, while
the efficacy of the spores was tested on spontaneous canine
tumours (57,70-72). The entire experimental material was
submitted to evaluation. An LD50 of Clostridium butyricum
CNRZ 528 spores could not be established since the rabbits
survived the 100-fold spore doses of the normally used ones
in domestic animals, i.e. 2x1010 spores per kg body weight.
Apart from occasional pyrogenic reactions, the overdoses
were without harm. Only histopathology gave reliable
judgement of microscopic tissue alterations, such as hepatic
resorption granulomas due to excessive spore phagocytosis.
The laboratory parameters of hematology and clinical
chemistry proved to be of minor informative value in all
animal species examined.
The clinical studies were conducted along the lines of the
Declaration of Helsinki and after all eligible patients had
given a written informed consent: 15 patients of clinical
phase I study with stage I and II mammary carcinoma (n=12)
and rectum carcinoma (n=3), serum specimen and intravenous
dosis of 1x108 spores per kg body weight, curative surgery 2
weeks thereafter, and serum specimens 1, 2, 3 weeks
postoperatively for antibody titre determination; 62 patients
of clinical phase II study with benign colon adenomas (n=34)
and cancer monitoring after curative surgery (n=22), moreover
mammary carcinoma (1), gastric carcinoma (1), colorectal
carcinoma (2), and melanoma (2), 5x107 spores per kg body
weight, serum specimens for Clostridium-tumour test like
clinical phase I study; in addition, 5 patients for clinical
phase I study with placebo.
Although spore suspensions were free of pyrogen (73), a
spore dose-dependent increase of temperature with 10 h-
latency was accompanied by macrophage activation,
interleukin-1 secretion, and high acute phase protein CRP-
levels (74) as well as spore elimination rates of blood with
half-life of 24 h. Patients who received half the spore dose
(phase II study) eliminated the spores more slowly with half-
life of 48 h (66). Given a non-specific host defence process
by non-thermal components of the fever syndrome, patients
of clinical phase I study were prognostically divided into two
groups: 2 out of 4 patients with mammary carcinoma and
saline solution as placebo had died, while 12 spore-treated
mammary carcinoma patients were free of metastases during
up to 9 years follow-up.
The complex anti-rod and anti-spore antibody response
had to be analysed with a combined set of complement
fixation, passive hemagglutination, and IgM-ELISA tests.
The total of individual titre values were subjected, by analogy
to the clostridial canine tumour serology, to an analysis of
discriminance (62,63). According to the protocol, healthy
volunteers were not admitted to participate in the study.
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Therefore, final assessment was based on 55 patients with
known (malignant and benign) neoplasias at the time of testing.
The tumour-Clostridium test achieved 86% sensitivity and
97% specificity (75).
While anti-spore antibodies were corresponding to the
systemic immune response of the spleen, anti-rod antibodies
were locally generated in tumour draining lymph nodes. Thus,
two processes of immunization were proceeding independently
of each other and the spore-test met the condition of a general
biological test for early detection of cancer (76). A positive
tumour-Clostridium test was indicative of neoplastic cell
growth in the organism with a sufficiently large growth fraction
and vascularization, and required an adequately large spore
dose for starting intratumorous rod growth. In conclusion, the
composition of the physiological bacterial intestinal flora might
have been decisive for the emergence of normal anti-rod and
anti-spore antibodies as observed in the sera of dogs, horses,
and humans, as against the conspicuous absence in sera of
cows and green monkeys.
4. Need for analytical experiments and theoretical
considerations
In the Malmgren-Flanigan experiment intravenously applied
spores of Clostridium tetani were distributed throughout the
organism, germinated selectively in anaerobic niches of
tumours to form vegetative rods, and led to lethal tetanus
intoxication of the host. It was a ‘black-box’ experiment which
left three questions unanswered: First, what is the relation
between a critical size of tumorous tissue and a distinct
quantity of tetanus spores which interact with each other and
cause a definable tetanus survival time of the tumour-bearing
mice? Second, what distinguishes normal tissue regeneration
and tumour cell proliferation with regard to anaerobic growth
conditions for Clostridia, in particular for toxigenic Clostridium
tetani, and is experimentally calcium chloride-induced wound
regeneration comparable with tumour growth to be defined in
cumulative tetanus lethality curves? Third, is the presence of
necrotizing tumorous tissue a necessary growth condition for
clostridial replication, or are proliferating eukaryotic cells
which are sufficiently supplied with oxygen and nutrients
involved and contribute to clostridial multiplication both in
tumour growth and in wound healing?
In analysing the Malmgren-Flanigan experiment spores
of Clostridium tetani can be considered as ‘probes’ for
anaerobiosis with the capability of germination, outgrowth,
replication, and possibly resporulation. Both steps of anaerobic
outgrowth and proliferation are accompanied with synthesis
and secretion of powerful tetanotoxin (tetanospasmin) which
acts on the synaptic inhibition of motoneurons in the spinal
cord (77,78). Mice are reacting to 5 pg of tetanotoxin with
specific tetanal symptoms beginning at the site of clostridial
propagation. For mice, the lethal dosis of tetanotoxin
corresponds to ~100 viable tetanus rods (79). Spores are
resistant to temperature, dessication, chemicals, and radiation.
Clostridium tetani Tulloch 3 was used for the analytical
experiments. Strain ATCC 8033 (Tulloch 1) of the Malmgren-
Flanigan experiment had identical effects.
Experiments with the mouse tumour-tetanus assay. With
developing the mouse tumour cell-tetanus spore assay and
due to the subcutaneous injection of mixed suspensions with
distinct numbers of tumour cells and tetanus spores, it was
possible to study in systematic and quantitative experiments
the interrelation of proliferating Ehrlich ascitic carcinoma cells
and replicating tetanus Clostridia in the triangle of the neck-
shoulder area. The spores got deposited in close spatial vicinity
of viable, mitotic tumour cells (37). Thus, anaerobic clostridial
rod growth and toxin secretion could take place in the inter-
stitial space between tumour cells, capillaries, and small blood
vessels (35).
At first, the experiments were based on the premise that
the early tumour cell proliferation is indicated by the tetanal
toxicoinfection. By referring to the main parameters of tetanus
incubation period and rate of tetanus incidence it was found
that either combination of tumour cells and tetanus spores
could lead to 50% tetanus lethality, namely large numbers of
tumour cells versus small doses of tetanus spores and vice
versa (80). Given that within certain limits the tumour cells
and tetanus spores can be replaced by each other, further
experiments supported the evidence that there is a direct
correlation between quantity of tumour cell inoculum, early
increase of tumour volume, period of tetanus incubation, and
incidence of tetanus reactivity. To such an extent, the
assumption seemed justified that the growth fraction of the
tumour with continued proliferation capacity represented the
active foci which provided the anaerobic micro-environment
of tetanus Clostridia to multiply and to produce tetanotoxin
(81,82). Only those tetanus spores were stimulated to
proliferation and toxin production which ‘hit’ on proliferating
clones of tumour cells. Thus, if one considered tumour growth
as the consequence of an imbalance between cell birth and
cell death of multiplicative cells the tumour-tetanus assay
indicated progressive growth kinetics of the tumour stem
cells (83).
On another occasion it could be demonstrated that in vitro
X-irradiation with 20 Gy of viable Ehrlich ascitic carcinoma
cells strongly diminished their power of mitotic growth
concomitant with a significant reduction of tetanus reactivity
of the mice after subcutaneous injection of the irradiated
tumour cells admixed with tetanus spores. It was unexpected
that the manometric values of respiration and glycolysis of
the 20 Gy-irradiated tumour cells remained unchanged
compared with non-irradiated Ehrlich carcinoma cells (84).
In an ‘experimentum crucis’ the cytostatic inhibition of solid
growing leukemia L1210 cells in DBA-NMRI hybrid mice
prevented the tetanus reactivity without being bacteriostatic
in vitro (79). Taken together, the S-shaped temporal course of
the tetanus lethality summation curve (start, steepness of slope,
termination) always corresponded with the differing growth
potential of syngeneic, allogeneic, and xenogeneic tumour cells
tested and permitted to analyse the transplantation resistence
to tumour growth in mice (82).
Experiments with wound-tetanus of the mouse. The quantitative
study of immediate cell replication with tumour-tetanus bore
resemblance to the hyperplastic process in wound repair
which, according to Haddow, can be identified with controlled
tumour growth (85). After taking this line of thought and
adopting the subcutaneous injection technique of tetanus
spores suspended in 5% CaCl2-solution (86) as a standard
of choice the obtained cumulated tetanus lethality curves of
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mice could equally be related to tetanus incubation time and
rate of tetanus incidence. It was noteworthy that the shape of
curve runs depended strictly on the number of tetanus spores
per dose, on the dose volume of calcium chloride solution,
and the body weight (age) of mice. When progressing from
dose volume of 0.01-0.1 ml, the tissue impairment leading to
wound regeneration was equal to 25 mm2, or 250 mm2 of
mean granulation surface, respectively. This specification
was valid for mice with 18-20 g of body weight.
According to Hewitt (87), subcutaneously injected particles
like transplantable cells or bacteria do not pass through the
intact ground substance and collagen mesh but keep adhered
at the rim of the traumatized area immediately adjacent to the
needle point. This process is one of filtration as the single
focus of the tetanus spore-deposit is much smaller than the
short-lasting infiltrated area produced. To some extent, the
CaCl2-tetanus spore assay of the mouse presented similar
experimental conditions as the tumour cell-tetanus spore assay.
In both experimental models the outcome of the clostridial
growth in loco was influenced primarily by mitotic cells
triggered to proliferate, such as transplanted viable tumour
cells, or wound granulation fibroblasts, respectively (88).
To distinguish wound-tetanus from tumour-tetanus two
groups of mice with equal tetanus lethality rates at the
beginning of the experiment were compared under tetanus
antitoxin treatment. The passive protection was of ~10 days
duration. Mice with post-sero tetanus were registered
exclusively among tumour-bearing mice. Obviously, pro-
liferation of tetanus rods had been sustained by permanently
cloning tumour cells (89).
Experiments with normal subcutaneous tissue of the mouse.
To re-evaluate the biological background of the Malmgren-
Flanigan experiment with tumour-free mice as controls it was
essential to study normal subcutaneous tissue showing very
low mitotic activity which serves to compensate for homeo-
static loss of single cells (90). That explains the problem of
extreme tetanus resistance in undamaged subcutaneous tissue.
Only very large doses of Clostridium tetani can violate the
natural inertness to tetanal toxico-infection of the cell homeo-
stasis maintained by dermal fibrocytes and fibroblasts. For
getting 50% tetanus reactivity in mice single subcutaneous
doses of several million tetanus spores suspended in physio-
logical sodium chloride solution were needed (91).
A remarkable biological phenomenon is the physiologic
24-h periodicity involving rhythms associated with the S and
M stages of the cell cycle (92,93). To prove the dependence
of tetanus reactivity on circadian rhythms in subcutaneous cell
homeostasis an extensive experiment was performed on mice
after 3 weeks of adaptation to 12 h-light-dark cycles. Twelve
groups of mice were injected subcutaneously large equal doses
of tetanus spores in successively 6-h intervals each for 3 days
and 3 nights beginning at 6 a.m. of day one and ending at 12
p.m. of night three. The outcome demonstrated clearly diurnal
rhythms of tetanus reactivity which were reproducible,
statistically significant, and in accordance with circadian
rhythms in mouse epidermal basal cell epithelium (94). The
values of maximum mitotic indices and of tetanus reactivity
were increased in the early morning at the beginning of light
and on the lowest level after outset of darkness (79). The result
of this study might be interpreted as the interrelationship
between tetanus spore germination, outgrowth, and replication
on the one hand and diurnal mitotic activity of subcutaneous
fibroblasts on the other hand.
5. Two-stage process of biological tumour-Clostridium
specificity
Working hypothesis for stage ‘one’ in tumour-tetanus infection.
Proceeding from the incipient sequential cell divisions
immediately after subcutaneous transplantation of tumour
cells or CaCl2-induced wound fibroblasts, there was no
fundamental difference concerning the concomitant clonal
propagation of tetanus rods. The obtained tetanus lethality
summation curves of mice resembled each other, with wound-
tetanus, however, starting and ending earlier. In both growth
processes simultaneously administered tetanus spores find
anaerobic micro-niches for germination, outgrowth, and rod
division. That is a contradictory statement of the theory that
tetanus toxicoinfection is strictly dependent on necrotic tissue
environment, i.e. almost oxygen-free zones of tissue (95), at
least in the initial phase of complex interplay between two
non-related live entities as oxygen-dependent malignant or
normal cells and peripheral hypoxia demanding tetanus
Clostridia. The basic evidence of this process can rather be
seen as a natural association between a cell in mitosis, its
close vicinity, and its generation of a temporarily hypoxic
micro-niche. The true nature of this association has been
analysed and characterized in more detail (96).
The working hypothesis can be formulated as follows:
In the primary stage of tetanus infection, there is strict
dependency on the singularity ‘one mitosis - one rod division’
under the condition that a clostridial spore has entered the
direct environment of a mitotic cell. The rationale behind this
hypothesis is that in the mitotic cycle of the cell (tumorous or
normal) there is a short interval during which its close environ-
ment becomes almost oxygen-deficient. In this way, the cellular
environment displays the precondition of a hypoxic micro-
niche which is caused by the high previous oxygen consumption
of the pre-mitotic cell. This is sufficient for a clostridial spore
germination or division of rod located there. The dependence
of the evolution of tetanus toxicoinfection on the growth rate
of ‘pacemaker cells’ has been observed in comprehensive
analytical experiments and has been documented in full detail
(79).
Experimental evidence for stage ‘two’ in tumour-tetanus
infection. Later, in the secondary stage of tetanus infection,
after exceeding a critical length of clonal division steps which
depend on the controlling dividing clones of ‘pacemaker
cells’, the propagating tetanus Clostridia may gain access to
avascular zones of hypoxic, necrotic tissue. An abundance of
tetanus rods will arise which is similar to in vitro growth of
anaerobic tetanus cultures. This will almost always lead to
death of tetanus.
The substantial base of this inference could be demonstrated
in a separate experiment on mice where tumour cells of Ehrlich
ascitic carcinoma were applied subcutaneously. The tetanus
spores were injected intravenously at day ‘0’ in a first group
of mice and at day ‘10’ after tumour cell transplantation in a
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second group. The control group was injected the combined
tumour cell-tetanus spore suspension subcutaneously at day ‘0’
(all groups of mice consisted of 50 animals each): Fig. 2a.
The result revealed the mitosis-dependent clostridial growth
in a vascularizing micro-tumour from the very beginning of
transplantation as clearly marked by the control group. The
same course was taken by the first part of the first test group.
The rising part of its tetanus lethality curve indicated the
successive clostridial colonization in the growing tumour by
blood born tetanus spores not yet eliminated through blood
clearance from the remaining intravenously injected tetanus
spores. It was noticeable that only when the progressive
tumour growth had produced avascular tissue districts, the
distinctly high and steep course of the cumulative tetanus
lethality curve of the second test group became manifested
and reflected the clostridial proliferation in the avascular
tumour region, independent of mitosis as had been described in
the Malmgren-Flanigen experiment.
Fig. 2b gives evidence of a parallel experiment with
wound-tetanus under analogous test conditions with tumour-
tetanus, namely groups and numbers of mice, modalities of
injection, point of time, and doses of tetanus spores injected.
Instead of tumour cells, 5% CaCl2-solution was injected
subcutaneously. The corresponding tetanus lethality summation
curves resembled each other concerning the first test group
and the control group. The wound-tetanus curve of the control
group started and ended earlier than the tumour-tetanus
control group.
A fundamental difference emerged from the cumulative
curve of tetanus lethality in the second test group, that is the
divergent course of wound-tetanus from tumour-tetanus
infection. In contrast to the steep and high tumour-tetanus
curve, the wound-tetanus curve tested with intravenously
applied tetanus spores at day ‘10’ (after setting the sub-
cutaneous tissue injury) faded away. This indicated the absence
of necrotizing events beyond 10 days in wound granulation
tissue and gave reason to point to the ‘pacemaking’ principle
which was effective in wound-tetanus infection throughout
the whole observation period of this experiment.
The genome of Clostridium tetani and possible implications.
The recently conducted sequencing and decoding of the entire
genome of Clostridium tetani (variant of the vaccine producing
strain Massachusetts E 88) revealed properties strongly
supporting the proposed principle of pacemaker cells (97,98).
First of all, in the genetic analysis several potential virulence
factors were identified, such as an array of surface-layer and
adhesion proteins. Noteworthy are preferences for proteins,
peptides, and amino acid degradation pathways as substrates
for fermentation. There are primary sodium ion pumps and
diverse sodium ion-dependent substrate symporters which
give evidence to extensive sodium ion bioenergetics. In this
context it is known that methionine, nicotinamide, L-lactic
acid, and sodium ions in phosphate-buffered solution are
essentials which are involved in spore germination whereby
sodium ions are most important (99). Moreover, a heme
oxygenase of Clostridium tetani has been characterized. In
cooperating with clostridial superoxide dismutase, it could
play a role in establishing oxygen tolerance and maintaining
reduced anoxic micro-environment. Its weak expression in
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Figure 2. Cumulative tetanus lethality curves following different modalities of spore application. (a) Control group (A) with subcutaneous injection of the
tumour cell-tetanus spore suspension (1.3x106 cells and 60 spores in 0.1 ml per dose) at day ‘0’. First test group (B) with subcutaneous tumour cell
transplantation (1.3x106 cells) and intravenous tetanus spore injection (3x106 spores) at day ‘0’. Second test group (C) with subcutaneous tumour cell
transplantation (1.3x106 cells) and intravenous tetanus spore injection (3x106 spores) at day ‘10’. Curve C represents the abundant mitosis-independent
clostridial growth indicating the presence of necrotic regions of the tumour 10 days after transplantation. (b) Control group (A) with subcutaneous injection of
the CaCl2-tetanus spore suspension (0.1 ml 5% CaCl2-solution and 60 spores per dose) at day ‘0’. Subcutaneous injection of CaCl2-solution (0.1 ml 5% CaCl2-
solution) and intravenous tetanus spore injection (3x106 spores in 0.1 ml per dose) at day ‘0’ (B). Subcutaneous injection of CaCl2-solution (0.1 ml 5% CaCl2-
solution) and intravenous tetanus spore injection (3x106 spores in 0.1 ml per dose) at day ‘10’ (C). Curve C represents the fading away of tetanal proliferation
indicating the gradual loss of mitotic wound granulation fibroblasts.
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exponential growth and strong expression in the stationary
phase of Clostridium tetani might give evidence to an ‘up and
down’ in temporarily aerobic conditions (100). To this extent,
the spatial proximity to proliferating eukaryotic cells and
their transient increased oxygen consumption might provide
optimal conditions for the ‘one-to-one’ correspondence of the
mitotic pacemaker cell and the clostridial rod division.
6. Non-mathematical description of the pacemaker
conception
The above pacemaker model of clostridial in vivo pro-
liferation [introduced by Schmidt et al (96) and Schneeweiss
et al (79)] should, although confirmed by experimental results,
be seen as a working hypothesis not yet sufficiently validated
and, thus, deserves further attention. To this extent, it is
necessary to define the main elements that influence in each
particular case the proliferation process of tetanus Clostridia
and, thus, the time of outbreak of tetanus in the experimental
animal. Note, however, that this process differs from animal to
animal despite the fact that identical experimental conditions
are used. Therefore, the influential elements must be treated
as statistical variables.
Essential parameters of the model. An important variable of
the mathematical model is the hit probability p. p measures
how many of the tumour cells subcutaneously injected
together with the spores reach the direct environment of a
mitotic (tumorous or normal) cell allowing the spores to
germinate. This number is drawn from certain statistical
distribution, that cannot be inferred for each particular case. p
depends on the structure of the pacemaker tissue, in
particular of its growth fraction, but not on the number of
actually injected spores. This number, however, determines
the actual number of hits according to the, then, given
statistical distribution.
The second central variable of the mathematical model is
the cloning probability (denoted by w). w measures the
probability that an already completed mitosis-dependent rod
division will be followed by (at least) one further step of
mitosis-controlled rod division. The number of rod divisions
in individual clostridial clones produced by the hit, thus,
becomes a random variable with a typical distribution, deter-
mined by w. It turned out that the structure of this distribution
is different in wound regeneration and for tumour growth. In
the latter, w is independent of the generation number, that is,
the number of completed generations. This can be explained
by the absence of growth regulation. In contrast, for wound
regeneration, w depends on the number of generations. This
leads to the fact that the number of rod divisions for each clone
of a hit has a significantly smaller variance. To describe the
number of rod divisions, for wound regeneration the Poisson
distribution and for tumour growth the geometric distribution
were used. In both cases, w is determined by the inverse of the
average number of division steps.
The third group of parameters concerns the cycle times of
the pacemaker cells. To describe these, the gamma distribution
was used. It is determined by two parameters (· and ß) that
are related to the average duration of a cell cycle and its
variance (101,102). The temporal evolution of clostridial
proliferation in a particular experimental animal is essentially
determined by the number of hits, the number of subsequent
steps of cloning, and the respective cell cycle durations.
Whether, and when tetanus disease breaks out in each
particular case depends on the toxin sensitivity of the animal.
It is assumed that there is a certain critical toxin level that
corresponds to a critical number of rods (K). K is another
parameter of the model that was estimated from experimental
data (96).
The parameters p, w, ·, ß, and K are, thus, the central
determinants of the pacemaker model. They should be able to
describe qualitatively and quantitatively the temporal course
of the untreated clostridial proliferation, in particular the
cumulative tetanus diseases in the experimental animals, given
that the pacemaker concept is indeed correct. Furthermore,
the model should yield correct predictions when therapeutic
measures are used, such as penicillin against rod growth, or
tetanus antitoxin to neutralize tetanus toxin. Using appropriate
extensions, the model has successfully been used (103,104).
Application of the pacemaker model to experimental data. A
mathematical model of a biological process is a theoretical
working hypothesis and cannot capture all aspects. Essential
is the postulate to include the main aspects and driving forces
of the process. If the model fulfills this criterion, it can be used
to analyse data and draw further conclusions. Deficiencies of
the model are revealed when it leads, for some experimental
results, to obvious contradictions. The pacemaker model is
based on stochastic concepts (probabilities and distributions).
For its realization and validation, the Monte-Carlo methods
were used. This means that the course of clostridial
proliferation in each experimental animal is considered a
realization of the stochastic pacemaker process and is
computationally verified. In each case, the experimental
details must be specified: number of spores applied, cell type
(tumour growth or wound regeneration), sample size, temporal
scheme, quantity of additional antitoxin, antibiotics, cytostatic
therapy if it was applied. At the beginning of a simulation,
for each parameter of the model, approximate values are
specified. A particular ‘experiment’ with a sample size of
50 animals simulated on the computer, then, corresponds to
50 realizations of the stochastic process as defined by the
model. The result is a cumulative tetanus lethality curve that
can be compared with the corresponding experimental
curve. As any single comparison of this type is obviously
insufficient, the computer programme produces numerous
curves of this type, with the aim to reproduce the
experimental curve as an average curve of the simulated
curves (compatibility). If this is not achieved using the initial
parameter specifications, the parameters are re-adjusted until
compatibility is reached. In this way, for instance, the
distribution of cell cycle durations can be estimated (using
the parameters · and ß). It can be double-checked using
other, independent methods, e.g. autoradiographic analysis of
the corresponding tumour cell population. At the same time,
the possibility of achieving compatibility using realistic
parameter values, and the ability of the model to predict the
outcome of experiments under alternative, not yet tested
conditions are used as criteria to evaluate the correctness of
the main assumptions of the model.
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Conclusive evidence of the pacemaker model. The main
conclusion from foregoing experimental investigations,
proceeding from the results of the Malmgren-Flanigan
experiment, was, that at least during the initial phase of
clostridial proliferation in warm-blooded organisms, a specific,
not yet generally accepted mechanism must be at work. This
mechanism enables Clostridia to utilize the energy
metabolism of proliferating eukaryotic cells for their own
growth. On the one hand, due to their increased oxygen
consumption, the host cells produce in their environment
temporarily and spatially limited hypoxic niches. On the
other hand, according to new insights based on genome
analyses of Clostridium tetani, Clostridia are able to home
in on these niches by their own metabolic activity, which
enables them to utilize the respective tissue for their
proliferation, even when there is a sufficient supply of
oxygen. That does not exclude intensified clostridial
multiplication in a later stage, based on tissue hypoxia
and developing necrosis due to insufficient oxygen supply.
However, homing is likely to be a necessary precondition
since intravenously applied spores scarcely reach existing
avascular tissue areas.
These conclusions were based on a large number of
animal experiments. It led to the working hypothesis that was
translated into a stochastic model which, in turn, could be
analysed using a computer programme. This allowed to
confront theoretical predictions stemming from the model
with the experimental results, and to determine the main
parameters of the model. The analysis showed a high degree
of compatibility (96,103,104).
7. Experimental biotherapy with genetically engineered
Clostridia
Since tumour lysis with Clostridium oncolyticum spores is
incomplete and, possibly, subject to non-specific systemic
incompatibility [‘acute tumour lysis syndrome’ (105)], the
genetic engineering with specific transforming protocols for
Clostridia became significant in pursuing the concept of
engineered Clostridia to produce anti-cancer drugs (106-108).
In 1988, Schlechte and Elbe were the first who attempted the
transformation of Clostridium oncolyticum with an Escherichia
coli plasmid-derived gene encoding colicin E3, a bacteriocin
with cancerostatic properties (109). Meanwhile, various
research groups have successfully engineered several
Clostridium species to producers of proteins in anti-tumour
therapy (110).
Clostridia-directed enzyme prodrug-therapy (CDEPT). In the
eighties, advances in Clostridia genetics made gene
manipulations of Clostridia available and created the novel
concept of CDEPT by Brown, Minton, and coworkers (111).
At first, the saccharolytic strain Clostridium acetobutylicum
(beijerinckii) and later the proteolytic strain Clostridium
sporogenes were used to produce an enzyme which can
metabolize a systemically applied non-toxic product into a
cytotoxic metabolite at the tumour site, to a large extent
sparing healthy tissues and organs. The Clostridia were trans-
formed with a recombinant plasmid carrying the Escherichia
coli gene for encoding the enzyme.
In a first successful experiment, a clone of Clostridium
sporogenes which is closely related to Clostridium oncolyticum
and carrying a recombinant plasmid with the Escherichia coli
gene encoding the bacterial enzyme cytosine deaminase (CD)
could be tested with tumour-bearing mice. This enzyme can
convert the systemically applied non-toxic prodrug 5-fluoro-
cytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU)
after intravenously injected recombinant clostridial spores
had yielded high efficiency of tumour colonization which
remained undiminished 14 days after a single injection of
spores. A significant growth delay of the tumours was achieved
by 5 times a week systemic injections of 5-FC. The tumour
extract from recombinant spore-treated mice increased the
in vitro cytotoxicity of 5-FC for tumour cell cultures by the
factor of 103. This anti-tumour effect was greater than with
5-FU alone (112). The efficient turnover of 5-FC carried out
by the Escherichia coli CD could be seen as an essential
step toward the tumour targeting strategy with clostridial
recombinant spores as selective delivery vectors (113,114).
A further approach to increase the spatial and temporal
specificity of the therapeutic proteins, such as cytosine
deaminase or murine tumour necrosis factor · (115,116), was
the introduction of a radio-inducible promoter-regulation.
Thus, putting the expression of the recombinant genes under
the inducible DNA-repair genes (SOS-repair) via irradiation
with 2 Gy into action means a temporal and spatial delivery
of the tumour-noxious agents in question. This will bring
an increase of therapeutic ratio and, in a way, become
advantageous to the classical gene therapy (117). It enables
to deliver the dose at the target tissue with specific activation
of the recombinant genes and presents a novel therapeutic
modality to deliver anti-cancer agents specifically in space
and time to the tumour site.
The crucial question of efficient colonizing tumours of
smaller size (<3 cm3) has been adressed with experiments
using vascular targeting compounds combined with the vector
system ‘Clostridium sporogenes’ to be tested in syngeneic rat
rhabdomyosarcomas after both Clostridium acetobutylicum and
Clostridium oncolyticum, following systemic administration,
had displayed superior colonization capacity (118,119). Among
smaller tumours of <1 cm3 there were such with little hypoxia
and no necrosis. A significant improvement of tumour
colonization was obtained, scored in clostridial colony
forming units, and showing strict relationship to the extension
of necrosis due to the action of the vascular targeting
compound.
Combination bacteriolytic therapy (COBALT). A prospective,
though daring step has been taken by selecting a strain out of
gas gangrene Clostridia, Clostridium novyi, by removing the
lethal ·-toxin gene from the wild-type strain through heating
the spores to inactivate the phage gene carrying the toxin. Of
400 clostridial colonies screened 3 had lost the toxin gene:
Clostridium novyi-NT. Large numbers of spores injected intra-
venously into mice were without side-effects, while abundant
intratumoral growth led to hemmorhagic necrosis exclusively
in tumour tissue (120). Both syngeneic mouse B16 melanomas
and xenogeneic human colorectal carcinomas with nude mice
showed tumour cell killing adjacent to the necrotizing tumour
centres in direct vicinity of germinating spores.
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Experimental bacteriolytic radiation therapy. To overcome
tumour hypoxia related resistance to radiation therapy,
combination with Clostridium novyi-NT treatment appeared
feasible since intratumoral crowding of multiplying Clostridia
eliminated those tumour components that are least sensitive
to radiation due to poor oxygenation. In traditional radiation
therapy tumour sensitivity is inversely correlated to tumour
size. It turned out that the efficacy of combined bacteriolytic
radiation therapy was not a function of tumour volume (ranging
from 50 mm3 to 1000 mm3) and immune status because both
syngeneic mouse B16 melanoma and xenogeneic human
tumour cell lines with immunocompromised nude mice showed
significantly improved results of radiotherapy through selective
clostridial destruction of hypoxic tumour districts (121).
Thus, Clostridium novyi-NT treatment was enhancing local
modes of radiation with external beam radiation of a Cs137
source (a total of 5 daily doses of 2 Gy each), or even more
effective, with experimental brachytherapy using I125
‘OncoSeeds’, respectively. In order to treat systemic disease,
radio-immunotherapy with I125 and I131 conjugated monoclonal
anti-CEA antibodies (from a myeloma clone secreting anti-
carcinoembryonic antigen monoclonal antibody) could be
applied. Clostridium novyi-NT spores were effective before
or after injection of labeled antibodies. Of 14 nude mice
carrying xenogeneic human colorectal adenocarcinoma two
were cured, whereas all mice treated with radio-immuno-
therapy alone were subjected to excessive tumour growth.
These data from various forms of radiation therapy suggested
that Clostridium novyi-NT application can potentiate standard
radiation regimens.
Bacteriolytic therapy and immunity. Notable were tumour
experiments conducted on syngeneic Balb/c mice and
allogeneic New Zealand rabbits that yielded ca. 30% cure rate
of animals after sole and single treatment with Clostridium
novyi-NT spores, despite viable rims of tumour cell, initially
remaining after intratumoral spore germination and massive
vegetative growth (122). Even large tumours completely
regressed: murine colorectal and renal carcinoma cells, injected
subcutaneously; rabbit VX2 minced tumour material,
inoculated intrahepatically. The initial accumulation of inflam-
matory neutrophils at the tumour periphery was followed,
within a few days, by monocytes and lymphocytes. Adoptive
transfer experiments determined CD8+ cells responsible from
mice cured with Clostridium novyi-NT application. Similar to
adjuvants, the infection with Clostridium novyi-NT, devoid
of lethal ·-toxin, stimulated an inflammatory response with
neutrophil-directed cytokines leading to a potent cellular anti-
tumour immune response.
8. Conclusion
The pacemaker model yielded important insights that can be
used for future development in the field of cancer diagnostics
and therapy after recent research on Clostridia has led to
advances in Clostridia genetics and its biotechnological
exploitation. As its working principle determines the first
stage of clostridial multiplication in the tumour and is
accompanied by anti-Clostridia induced immune reactions, the
scope for approaches to treatment and diagnostic modalities
of early stages of cancer and metastases should be envisaged.
Existing applications in the experimental field, fitted with
tumour-specific supplements, are based on the precondition
that the tumours to be treated have pronounced hypoxic
tissue regions for mass production of Clostridia. If it must be
assumed that abundant hypoxic tumour areas are not
essential for clostridial reproduction, novel strategies, such as
‘Combined bacteriolytic therapy’ coupled with anti-
Clostridia immune activation will come into play.
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